Core Viewpoint - QuidelOrtho Corporation is expanding its QUICKVUE portfolio with the introduction of the QUICKVUE Influenza + SARS Test, aimed at enhancing point-of-care diagnostic testing capabilities for respiratory illnesses [1][3]. Product Features and Benefits - The QUICKVUE Influenza + SARS Test allows for rapid, simultaneous detection of influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes [2][5]. - This test is designed for use in various healthcare settings, including physician office laboratories, urgent care centers, emergency departments, and pharmacies, facilitating timely treatment decisions and improved patient outcomes [2][3]. - The test is a CLIA-waived, 510(k)–cleared immunoassay, emphasizing its reliability and efficiency in differentiating between COVID-19 and seasonal flu infections [1][3]. Market Position and Strategy - The launch of the QUICKVUE Influenza + SARS Test reinforces QuidelOrtho's leadership in point-of-care respiratory testing and expands its portfolio of respiratory solutions [3][4]. - The company aims to provide healthcare professionals with cost-effective solutions that streamline clinical decisions and manage seasonal surges in respiratory infections [3][4]. - QuidelOrtho's commitment to innovation is evident in its continuous development of diagnostic solutions that improve patient outcomes across various healthcare settings [4].

Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society MeetingSeptember 19, 2025 8:30 AM EDT | Source: Telo Genomics Corp.Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease (" ...

Core Viewpoint - QuidelOrtho Corporation (NASDAQ:QDEL) is recognized as one of the best small-cap stocks to buy, with RBC Capital raising its price target from $60 to $62 while maintaining a Buy rating [1][3]. Financial Performance and Strategy - QuidelOrtho has successfully completed a series of transactions to refinance its debt structure, extending debt maturities and reducing required amortization payments, which enhances financial flexibility [2][3]. - The company prioritizes reducing total debt and net debt leverage, improving debt covenant terms, and enhancing cash flow to support future growth [3]. Market Growth and Opportunities - The company has experienced significant growth in international markets during Q2 FY2025, particularly in Latin America, Japan, Asia Pacific, and EMEA regions [4]. - QuidelOrtho is focusing on its molecular strategy, including the acquisition of LEX Diagnostics, which is expected to enhance its growth potential [4]. Analyst Insights - As of September 5, the average price target for QuidelOrtho is $37.50, indicating an upside potential of approximately 30.75% from current levels [5]. - QuidelOrtho operates in various segments, including Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics [5].

Core Insights - Myriad Genetics announced the publication of a study in The Lancet Oncology, showcasing the effectiveness of its Precise MRD test for patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) [1][4] Study Findings - The study aimed to assess the benefits of ultrasensitive MRD testing in oligometastatic ccRCC patients, revealing that circulating tumor DNA (ctDNA) levels correlate with responses to metastasis-directed radiation therapy (MDT) [2][3] - The Precise MRD test successfully detected ctDNA in patients with low tumor burden, potentially allowing them to delay or avoid systemic treatments, thus reducing side effects and enabling treatment de-escalation [2][3] Key Metrics - In the Phase 2 trial, patients who were ctDNA negative experienced nearly double the median systemic therapy-free survival compared to ctDNA positive patients [3] - 94% of patients tested at baseline had ctDNA levels below 100 ppm, indicating the effectiveness of the ultrasensitive testing [7] - Patients who tested negative for ctDNA maintained MDT for a median of 54 months, while those who tested positive progressed to systemic therapy within a median of 27 months [7] - Overall survival rates for ctDNA negative patients on MDT were 94% at two years and 87% at three years [7] Test Overview - Myriad's Precise MRD Test utilizes whole genome sequencing to monitor numerous tumor-specific variants, providing high sensitivity and quantification of ctDNA in cancer patients [5] - The test can be employed throughout a patient's clinical journey, starting from diagnosis and continuing through treatment [5] Company Background - Myriad Genetics specializes in molecular diagnostic testing and precision medicine, aiming to enhance health and well-being through advanced genetic and genomic testing solutions [8]

Results published in the Journal of Clinical PsychopharmacologySALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant i ...

SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chie ...

Core Insights - The Cancer Risk Survey reveals a contradiction in women's attitudes towards health screenings, with 80% expressing fear of screenings but 75% finding reassurance in advanced screenings like genetic testing [1][2][3] Group 1: Survey Findings - 37% of women believe genetic testing can aid in managing breast health, yet around 40% are unaware of its existence [2] - Only 14% of respondents have undergone genetic testing, while over 25% of women in OB/GYN settings qualify for hereditary cancer testing [2][3] - More than 50% of respondents consider knowing their parents' health history very important, but only about 30% know it very well [4] Group 2: Importance of Genetic Testing - Genetic tests, such as the MyRisk Hereditary Cancer Test with RiskScore, provide critical information about hereditary cancer risks, leading to more frequent screenings if necessary [3][6] - Combining genetic insights with family history can help calculate a woman's five-year and lifetime risk of breast cancer, offering options for medical management [6] Group 3: Survey Methodology - The nationwide survey was conducted online with a sample of 1,002 English-speaking adult females, including 404 who met hereditary cancer risk testing criteria [7] - The margin of error for the total sample is +/- 3.1%, and for high-risk women, it is +/- 4.9% at a 95% confidence level [8]

Core Points - Myriad Genetics, Inc. will hold its second quarter 2025 earnings conference call on August 5, 2025, at 4:30 PM ET [1] - The company's quarterly earnings will be released the same day after market close [1] - Management will provide a financial overview and business update during the call [1] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine [3] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3] Investor Information - A live webcast of the conference call will be available on Myriad's Investor Relations website [2] - Participants can register for the call to receive a dial-in number and unique PIN [2] - An archived version of the webcast will be accessible after the call [2]

Core Insights - Athena Diagnostics, a subsidiary of Quest Diagnostics, has launched a new laboratory test service aimed at identifying genetic causes of ataxia, a group of progressive neurological disorders affecting movement and coordination [1][2]. Company Overview - Athena Diagnostics specializes in diagnostic testing for neurological diseases and offers innovative tests for conditions such as Alzheimer's disease and muscular dystrophy [7]. - Quest Diagnostics is a leading provider of diagnostic information services and has collaborated with PacBio to develop the new ataxia test using advanced sequencing technology [1][3]. Technology and Methodology - The new test utilizes PacBio's PureTarget sequencing method, which is designed to identify long repeating DNA sequences that conventional sequencing technologies may miss [2][3]. - The test will confirm initial screening results obtained through polymerase chain reaction (PCR) testing, enhancing the quality of confirmatory testing for ataxia [2][5]. Clinical Relevance - A study indicated that the PureTarget gene panel could identify specific repeating gene patterns associated with Spinocerebellar ataxia type 10, potentially guiding care decisions based on the age of disease onset [4]. - The prevalence of ataxia in children is reported to be 26 per 100,000, with 10 per 100,000 cases attributed to genetic factors [6]. Future Developments - Athena Diagnostics is exploring the development of additional tests based on PacBio technology to enhance carrier screening capabilities [3].

Core Insights - The podcast episode discusses the increasing complexities of substance use detection and care in emergency departments, emphasizing the need for rapid diagnostic testing to prevent drug overdose deaths [3][8] - Vonda McAllister, Director of Global Product Management at QuidelOrtho, highlights the importance of continuous monitoring and comprehensive toxicology screening in addressing the crisis of drug overdoses [5] Industry Trends - There is a rising prevalence of potent synthetic drugs such as fentanyl, xylazine, and nitazines, which complicates overdose presentations [8] - The limitations of Narcan (naloxone) are becoming evident, with a growing need for repeated doses due to the potency of new opioid analogs [8] - California's "Tyler's Law" mandates fentanyl testing in suspected overdose cases, reflecting a legislative response to the crisis [8] Company Overview - QuidelOrtho Corporation is a global provider of innovative diagnostic testing solutions, focusing on various health areas including infectious diseases and cardiac biomarkers [7] - The company aims to transform diagnostics into a healthier future through science, innovation, and accessibility [7]